Oxford BioDynamics and Kings College London to advance rheumatoid arthritis treatment from BioPharma-Reporter.com
The collaboration comes on the back of the successful APIPPRA trial – the largest RA prevention trial to date, which investigated the biological antirheumatic drug and was led by Professor Andy Cope. According to trial data, 92.8% of patients treated with …